Ruxolitinib

Anter

• Ma mua o ka lawe ʻana i ruxolitinib,
• Hoʻokumu paha ʻo Ruxolitinib i nā hopena ʻaoʻao. E haʻi i kāu kauka inā koʻikoʻi kekahi o kēia mau ʻōuli a mai hele aku paha:
• Hiki i kekahi o nā hopena ʻaoʻao ke koʻikoʻi. Inā ʻoe e ʻike i kekahi o kēia mau ʻōuli, e kāhea koke i kāu kauka:
• Hiki i nā ʻōuli o ka overdose ke hoʻopili i kēia mau mea:

Hoʻohana ʻia ʻo Ruxolitinib e mālama i ka myelofibrosis (kahi maʻi ʻaʻai o ka iwi iwi kahi e kuapo ʻia ka iwi iwi e nā ʻili maka a e hoʻemi ai i ka hana ʻana o ke koko). Hoʻohana ʻia ia e mālama i ka polycythemia vera (PV; kahi lohi e ulu nei i ka maʻi ʻaʻai o ke koko kahi e hana ai ka iwi iwi i nā ʻulaʻula koko he nui) i ka poʻe i hiki ʻole ke mālama kūleʻa ʻia me ka hydroxyurea. Hoʻohana ʻia ʻo Ruxolitinib e mālama i ka hoʻopili ʻana me ka maʻi hoʻokipa (GVHD; kahi pilikia o ka hematopoietic stem-cell transplant [HSCT; kahi hana e hoʻololi ai i ka iwi iwi maʻi me ka momona iwi maikaʻi]) i nā mākua a me nā keiki he 12 mau makahiki a ʻoi paha i mālama ʻia kūleʻa me nā lāʻau steroid. Aia ʻo Ruxolitinib i kahi papa o nā lāʻau i kapa ʻia nā kinase inhibitors. Hana ia e mālama i ka myelofibrosis a me ka PV ma ke kāpae ʻana i nā hōʻailona e hoʻonui ai i nā hunaola maʻi ʻaʻai. Kōkua kēia i mea e hōʻoki ai i ka hoʻolaha ʻana o nā hunaola maʻi ʻaʻai. Hana ia e mālama iā GVHD ma o ka pale ʻana i nā hōʻailona o nā hunaola e kumu iā GVHD.

Hele mai ʻo Ruxolitinib ma ke ʻano he papa e lawe ma ka waha. Lawe mau ʻia me ka ʻai ʻole a i ʻole ʻelua mau manawa i ka lā. Lawe iā ruxolitinib ma nā manawa like i kēlā me kēia lā. E hāhai pono i nā ʻōkuhi i kāu lepili kuhikuhi, a nīnau i kāu kauka a kauka paha e wehewehe i kahi ʻāpana āu i maopopo ʻole ai. Lawe pono iā ruxolitinib e like me ke kuhikuhi. Mai lawe i ka mea ʻoi aku a liʻiliʻi paha o ia mea, a lawe pinepine iā ia ma mua o ka mea i kauoha ʻia e kāu kauka.

Inā mālama ʻia ʻoe no myelofibrosis a i ʻole PV hiki i kāu kauka ke hoʻomaka iā ʻoe ma kahi haʻahaʻa o ruxolitinib no nā pule ʻehā mua o ka hoʻomaʻamaʻa ʻana, a hoʻonui iki i kāu lāʻau ma hope o kēlā manawa, ʻaʻole ʻoi aku i hoʻokahi manawa i kēlā me kēia 2 pule. Inā mālama ʻia ʻoe no GVHD hiki i kāu kauka ke hoʻomaka iā ʻoe ma kahi haʻahaʻa o ruxolitinib a hoʻonui i kāu lāʻau ma hope o 3 mau lā o ka hoʻomaʻamaʻa.

E ale i nā papa holoʻokoʻa; mai nahu a paopao iā lākou.

Inā ʻaʻole hiki iā ʻoe ke loaʻa ka ʻai ma ka waha a loaʻa kahi paipu nasogastric (NG), e haʻi paha kāu kauka iā ʻoe e lawe iā ruxolitinib ma o ka nasogastric (NG) Tube. E wehewehe kāu kauka a kauka paha pehea e hoʻomākaukau ai i ka ruxolitinib e hāʻawi ma o kahi pūpū NG.

E kauoha kāu kauka i nā hoʻokolohua koko ma mua a i kāu wā e ʻike ai pehea ʻoe e hoʻopili ʻia ai e kēia lāʻau. Hiki i kāu kauka ke hoʻonui a hōʻemi paha i kāu lāʻau o ruxolitinib i kou wā e lapaʻau ai, a i ʻole e haʻi paha iā ʻoe e haʻalele i ka lawe ʻana i ka ruxolitinib no kekahi manawa. Aia kēia i ka maikaʻi o ka hana ʻana o ka lāʻau iā ʻoe, nā hopena hōʻike lab, a inā ʻike ʻoe i nā hopena ʻaoʻao. E kamaʻilio me kāu kauka e pili ana i kou ʻano i kāu mālama ʻana. E hoʻomau i ka lawe ruxolitinib ʻoiai ʻoe e manaʻo maikaʻi. Mai hōʻoki i ka lawe ʻana i ruxolitinib me ka walaʻau ʻole ʻana me kāu kauka. Inā hoʻoholo kāu kauka e hōʻoki i kāu lāʻau me ruxolitinib, hiki i kāu kauka ke hoʻemi haʻahaʻa i kāu lāʻau.

E noi i kāu kauka lāʻau a kauka paha no kahi kope o ka ʻike a ka mea hana no ka mea maʻi.

Kau ʻia kēia lāʻau no nā hoʻohana ʻē aʻe; e noi i kāu kauka a kauka paha no ka ʻike hou aku.

Ma mua o ka lawe ʻana i ruxolitinib,

• e haʻi i kāu kauka a me ka kauka inā he maʻi ʻoe i ka ruxolitinib, nā lāʻau ʻē aʻe, a i ʻole kekahi o nā mea hoʻohui i ruxolitinib. E noi i kāu kauka lāʻau no kahi papa inoa o nā mea hoʻohui.
• e haʻi i kāu kauka a me ka mea kauka lāʻau i nā lāʻau lapaʻau, nā wikamina, nā mea hoʻopihapiha, a me nā huahana lāʻau āu e lawe nei a hoʻolālā paha e lawe. E hoʻomaopopo pono e ʻōlelo i kekahi o nā mea aʻe: nā lāʻau antifungal me itraconazole (Sporanox), ketoconazole, a me voriconazole (Vfend); carbamazepine (Carbatrol, Equetro, Tegretol, a me nā mea ʻē aʻe); clarithromycin; efavirenz (Sustiva, i Atripla, Symfi); fluconazole (Diflucan); Nā mea hoʻopuka protease HIV me indinavir (Crixivan), nelfinavir (Viracept), ritonavir (Norvir, ma Kaletra, Viekira Pak), a me saquinavir (Invirase); mibefradil (Posicor); nefazodone; nevirapine (Viramune); phenytoin (Dilantin, Phenytek); pioglitazone (Actos, ma Oseni, Duetact); rifabutin (Mycobutin); rifampin (Rifadin, Rimactane, ma Rifamate, Rifater); telaprevir (Incivik); a me telithromycin (Ketek). Pono paha kāu kauka e hoʻololi i nā kaha o kāu mau lāʻau a nānā pono iā ʻoe no nā hopena ʻaoʻao.Hiki paha i nā lāʻau ʻē aʻe ke launa pū me ruxolitinib, no laila e ʻike pono i kāu kauka e pili ana i nā lāʻau a pau āu e lawe nei, a ʻo nā mea ʻaʻole i ʻike ʻia ma kēia papa inoa.
• e haʻi i kāu kauka i nā huahana lāʻau āu e lawe nei, ʻo ka wort ʻo St.
• e haʻi aku i kāu kauka inā he anemia kou, he maʻi, inā ʻoe ma ka dialysis, a i ʻole inā kokoke ʻoe i kahi mea i loaʻa i ka maʻi puʻupuʻu (TB, kahi maʻi puʻupuʻu nui) a i kipa ʻia a i noho paha ma kahi o ka TB maʻamau. E haʻi pū aku i kāu kauka inā loaʻa iā ʻoe inā he TB paha ʻoe, ke kiʻekiʻe o ke kōkō, ka maʻi ʻaʻai o ka ʻili, ka maʻi hepitis B a i ʻole nā ​​maʻi ʻē aʻe, a i ʻole nā ​​maʻi puʻupaʻa.
• E haʻi i kāu kauka inā hāpai ʻoe, e hoʻolālā e hāpai, a i ʻole e hānai umauma ana. Inā hāpai ʻoe i ka lawe ʻana i ruxolitinib, e kāhea i kāu kauka. ʻAʻole pono ʻoe e hānai i ka umauma i ka wā e lawe ana i ruxolitinib a no 2 mau pule ma hope o kāu hopena hope loa.

Inā ʻaʻole haʻi kāu kauka iā ʻoe, e hoʻomau i kāu papaʻai maʻamau.

E haʻalele i ka lāʻau i haʻalele ʻia a hoʻomau i kāu papa hana maʻamau. Mai lawe i kahi lāʻau pālua e pani no kahi mea i hala.

Hoʻokumu paha ʻo Ruxolitinib i nā hopena ʻaoʻao. E haʻi i kāu kauka inā koʻikoʻi kekahi o kēia mau ʻōuli a mai hele aku paha:

• ʻūpā
• ʻeha poʻo
• luhi
• nāwaliwali
• pokole o ka hanu
• loaʻa kaupaona
• ʻenekini
• abdominal eha
• pāhoehoe
• kōpaʻa
• nausea
• ʻūlili
• hūwī
• ʻehaʻeha a ʻeha pū paha
• ka pehu ʻana o nā lima, nā wāwae a i ʻole nā ​​ʻāpana ʻē aʻe o ke kino

Hiki i kekahi o nā hopena ʻaoʻao ke koʻikoʻi. Inā ʻoe e ʻike i kekahi o kēia mau ʻōuli, e kāhea koke i kāu kauka:

• ʻokoʻa a kaumaha paha ke kahe ʻana a i ʻole ʻūpā
• fiva, ʻeha puʻu, ʻalalā, ʻū, ʻeha o ka umauma, sweats i ka pō, pinepine, ʻeha, urination urinary, a me nā hōʻailona o ka maʻi.
• ke ahi, ke kani ʻana, ka ʻili ʻana, a me ka ʻili o ka ʻili ma kekahi ʻaoʻao o ke kino a i ʻole ke alo me ka ʻeha a ʻeha paha i ʻike ʻia i kekahi mau lā ma hope.
• nā ʻeha hou, nā puʻupuʻu, a i ʻole ka hoʻoliʻiliʻi a i ʻole nā ​​hoʻololi ʻē aʻe i ka ʻili
• ʻili ʻulaʻula, luhi, a i ʻole ka liʻiliʻi o ka hanu (ʻoiai ke hana nei)
• paʻakikī e neʻe a mālama paha i kāu kaulike, nāwaliwali o nā wāwae a i ʻole nā ​​lima e hoʻomau i ka maikaʻi, paʻakikī i ka hoʻomaopopo ʻana a i ʻole ʻōlelo ʻana, nalo ʻana o ka hoʻomanaʻo, nā pilikia ʻike, a i ʻole nā ​​loli i ke ʻano.

Hoʻokumu paha ʻo Ruxolitinib i nā hopena ʻē aʻe. Kāhea i kāu kauka inā he pilikia ʻokoʻa kāu i ka lawe ʻana i kēia lāʻau.

Inā ʻoe e ʻike i kahi hopena koʻikoʻi, e hoʻouna ʻoe a i ʻole kāu kauka i kahi hōʻike i ka papahana hōʻike ʻino a MedWatch Adverse Event Food (FDA) ma ka pūnaewele (http://www.fda.gov/Safety/MedWatch) a i ʻole kelepona. 1-800-332-1088).

E mālama i kēia lāʻau i loko o ka pahu i komo ai, pani paʻa ʻia, a ʻaʻole hiki i nā kamaliʻi. E mālama iā ia i ka mahana wela o ka lumi a ma kahi o ka wela a me ka momona (ʻaʻole i ka lua.

Pono e hoʻolei ʻia nā lāʻau i koi ʻole ʻia i nā ala kūikawā e hōʻoia i ka hiki ʻole i nā holoholona, ​​nā keiki, a me nā poʻe ʻē aʻe ke hoʻopau iā lākou. Eia nō naʻe, ʻaʻole pono ʻoe e kaomi i kēia lāʻau i ka lua. Akā, ʻo ke ala ʻoi loa e hoʻolilo i kāu lāʻau i loko o kahi papahana hoʻihoʻi lāʻau. E kamaʻilio me kāu kauka lāʻau a kāhea paha i kāu ʻōpala a me nā hana hoʻopōʻaiapuni kūloko e aʻo e pili ana i nā papahana hoʻihoʻi i kou kaiāulu. E ʻike i ka pūnaewele palekana o kā FDA's Disposal of Medicines (http://goo.gl/c4Rm4p) no ka ʻike hou aku inā ʻaʻohe ou komo i kahi papahana hoʻihoʻi.

He mea nui e mālama i nā lāʻau āpau mai ka maka a hiki i nā keiki e like me nā ipu (e like me nā minder pill i kēlā me kēia pule a me nā mea no nā kulu maka, nā kalima, nā pākuʻi, a me nā inhalers) ʻaʻole pale keiki a hiki i nā keiki ʻōpio ke wehe maʻalahi iā lākou. No ka pale ʻana i nā keiki ʻōpio mai ka lāʻau make, laka mau i nā pāpale palekana a kau koke i ka lāʻau i kahi palekana - kahi i luna a mamao a mai ko lākou alo a hiki. http://www.upandaway.org

I ke kumu o ka overdose, e kāhea i ka helpline kaohi lāʻau make ma 1-800-222-1222. Loaʻa ka ʻike ma ka pūnaewele ma https://www.poisonhelp.org/help. Inā ua hina ka mea i hoʻomāinoino ʻia, loaʻa ka hopu ʻana, pilikia i ka hanu ʻana, a i ʻole hiki ʻole ke ala aʻe, e kāhea koke i nā lawelawe kūikawā ma 911.

Hiki i nā ʻōuli o ka overdose ke hoʻopili i kēia mau mea:

• kahe koko ʻole ʻana a palapū paha
• ʻūpā
• ʻeha poʻo
• luhi
• fiva, ʻāʻī puʻupuʻu, ʻalalā, ʻū, a me nā hōʻailona ʻē aʻe o ka maʻi

E mālama i nā manawa a pau me kāu kauka a me ka hale hana.

Mai ʻae i kahi mea ʻē aʻe e lawe i kāu lāʻau. E nīnau i kāu kauka lāʻau i nā nīnau āu e pili ana i ka hoʻopiha hou ʻana i kāu kuhikuhi.

He mea nui iā ʻoe e mālama i kahi papa inoa i kākau ʻia a me nā lāʻau lapaʻau ʻole (over-the-counter) lāʻau āu e lawe nei, a me nā huahana e like me nā huaora, nā minelala, a i ʻole nā ​​mea hoʻopiliʻai aʻe. Pono ʻoe e lawe i kēia papa inoa me ʻoe i kēlā me kēia manawa ke kipa ʻoe i ke kauka a i ʻole inā ʻae ʻia ʻoe i kahi haukapila. He ʻike nui nō hoʻi ia e lawe pū me ʻoe inā pilikia ʻo ka pilikia.

• ʻO Jakafi